Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

NAPLES, Fla., Oct. 7, 2021 —Enveric Biosciences(NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming October conferences:

  • A.G.P.’s Biotech & Specialty Pharma Conference to be held virtually on Wednesday, October 13, 2021.
  • KCSA Psychedelics Investor Conference to be held virtually at VirtualInvestorConferences.com from October 13-14, 2021. Dr. Tucker will present live on Wednesday, October 13th at 11:30 a.m. ET. Register to attend here.

For more information about the conferences, or to schedule a one-on-one meeting with Enveric’s management team, please contact your representatives directly, or send an email to A.G.P. at agpevents@allianceg.com or KCSA Strategic Communications at envericbio@kcsa.com.

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric’s robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com

Media Contacts
Raquel Cona / Joe McIntyre
KCSA Strategic Communications
212.896.1204 / 856.381.8996
rcona@kcsa.com / jmcintyre@kcsa.com

Cision View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-october-2021-301394758.html

SOURCE Enveric Biosciences

Lobe Sciences to Present at the BioFuture 2021 & MoneyShow Virtual Expo Investor Conferences

Lobe Sciences to Present at the BioFuture 2021 & MoneyShow Virtual Expo Investor Conferences

Vancouver, British Columbia–(Newsfile Corp. – October 5, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present virtually at the BioFuture 2021 Conference taking place October 5-6, 2021, and will present virtually at the MoneyShow Virtual Expo taking place October 5-7, 2021

Philip Young, CEO and Director, will have his presentation streamed throughout the conference at the Lobe virtual booth during the BioFuture 2021 Conference and will present at the MoneyShow Virtual Expo at 12:40 P.M. ET on Thursday, October 7, 2021.

The events are accessible using the following links:

BioFuture 2021: https://biofuture.com/biofuture-registration/.
MoneyShow Virtual Expo: https://online.moneyshow.com/2021/october/virtual-expo/.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Dr. Molly Maloof, Physician, Technologist and Entrepreneur, To Keynote At Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Dr. Molly Maloof, Physician, Technologist and Entrepreneur, To Keynote At Meet Delic: The World’s Premiere Psychedelic and Wellness Event

Meet Delic, the revolutionary, two-day immersive edutainment experience for the world’s leading psychedelic and wellness thought and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, October 5, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSEDELC) (OTCQBDELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced that Dr. Molly Maloof, MD, will serve as a keynote speaker at Meet Delic on November 6. Dr. Maloof has worked with investors, entrepreneurs, and executives to optimize their health and consulted with more than 45 companies in the digital health, consumer health, and biotechnology industries needing help with clinical strategy, product development, clinical research and scientific marketing. She is also the co-founder of the Psychedelic Clubhouse on the Clubhouse app where she co-hosts the Psychedelic News Hour.

Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness, and business with like-minded visionaries. Dr. Maloof’s keynote, Aphrodisiacs and Psychedelics: A History of Medicine for Love, will explore psychedelic aphrodisiacs and provide historical, modern day and future contexts for the role of psychedelics in human relationships.

“I’m super excited to speak at Meet Delic, the premier consumer psychedelic conference,” said Maloof. “They are truly making history by bringing people together in Las Vegas during a time when we need community and connection more than ever. I couldn’t be more honored to speak at such an important conference in such a pivotal point in history. It’s going to be a blast.”

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo.

“Molly has deep experience in the space where health, wellness, technology and business intersect,” said Delic co-founder, Jackee Stang. “Her entrepreneurial spirit drives her to create new channels for people to learn about optimizing their health and wellness, and we are happy to have Molly speak at Meet Delic.”

The twenty hours of panels and keynotes will include an array of topics such as Psychedelics and the Search for TruthWhy Are Psychedelics Medicine?, The Shortcomings of Wellness, PTSD Reset and RecoveryPsychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World, Psychedelics and Sobriety: The Next Frontier in RecoveryMicrodosing, Psychedelic Activism, Digital Dosing: Technology & Innovation Powering PsychedelicsHow Psychedelics Can be Effectively Used for Physical Optimization, and Drug Use for Grown-Ups. Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic RadioDelic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Novamind to Deliver Keynote at PSYCH Investor Summit on October 7, 2021

Novamind to Deliver Keynote at PSYCH Investor Summit on October 7, 2021

Chief Medical Officer will join expert panel on data and tech in psychedelic-assisted psychotherapy

TORONTO, ON / October 4, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will participate in the PSYCH Investor Summit: Data and Technology taking place virtually on October 7, 2021 (the “Summit”).

Novamind’s Chief Medical Officer, Dr. Reid Robison, will open the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Dr. Robison will outline the challenges and opportunities that have brought us to this exciting moment in mental health and share how Novamind’s unique operating model of clinics and research sites increases access to psychedelic medicine. Dr. Robison will also touch on the role of technology in the mainstream adoption of psychedelic therapies.

Following the keynote, Dr. Robison will join industry leaders in an expert panel, “When psychedelics meets Silicon Valley” to discuss pre-treatment, monitoring and post-treatment applications in psychedelic-assisted therapy.

Novamind is pleased to be featured in the third edition of PSYCH’s “The Psychedelics as Medicine Report”. The report is now available for free at: www.psych.global/report/.

For more information about the Summit and to register for free, visit: www.psych.global/summit/.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20

Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20

Anexpert panel will present and discuss new potential treatments for Alcohol UseDisorder and binge drinking

TORONTO,Oct. 1, 2021—via InvestorWire – Clearmind Medicine Inc. (CSE:CMND) (“Clearmind” or the “Company“), a psychedelicmedicine biotech company focused on the discovery and development of novelpsychedelic-derived therapeutics to solve widespread and undertreated healthproblems, is pleased to announce it will be hosting Psychedelics ForAlcoholism, a free, live virtual event highlighting new potentialtreatments for alcohol use disorder and binge drinking.

The online event will be held Oct. 20, 2021, starting at 12 p.m.EST/9 a.m. PST; registration is open and free to all. The event will includebrief presentations by featured speakers, followed by a discussion with aquestion-and-answer session.

The Company has curated a panel of scientists, thought leaders,therapists, and pundits to sharetheir experiences and educate participants on the mounting evidence suggestingthe effectiveness of psychedelics, and specifically MEAI, in the regulation ofexcessive drinking .

Representatives from the Company will also provide an updateon Clearmind’s MEAI-based medicines and their potential for the treatment ofAlcohol Use Disorder and binge drinking.

AdiZuloff-Shani, Ph.D., CEO of Clearmind, stated, “We’re in the middle of a PsychedelicRenaissance that is revolutionizing the way we treat mental disorders. We putthis event together to increase awareness of the advances being made in thefield, and more specifically generate awareness of the work Clearmind is doingwith regard to alcohol use and binge drinking.”

“Togetherwith our sponsors and partners, we are eager to share our progress and provideaccess to accurate information to interested communities, including mentalhealth practitioners, researchers, potential patients, investors and thegeneral public,” Zuloff-Shaniconcluded.

Following is a list ofour panelists and partners. To register for the event, or learn more aboutPsychedelics for Alcoholism, visit the event website.

Among our featured speakers and panelists: Shannon Smadella, moderator; Adi Zuloff-Shani, Ph.D., chief executive officer at Clearmind; Mark Haden, Advisory Board member,Clearmind; Terri Freeland, construction industry professional; and Dr. JeffMorley, registered psychologist.

Partners include: Canadian Psychedelic Association, WorldPsychedelics Day, McKennaAcademy of Natural Philosophy™, and Insight Global.

About Clearmind Medicine Inc.

Clearmind (CSE: CMND) is a psychedelicpharmaceutical biotech company focused on the discovery and development ofnovel psychedelic-derived therapeutics to solve widespread and underservedhealth problems, including alcohol use disorder. Its primary objective is toresearch and develop psychedelic-based compounds and attempt to commercializethem as regulated medicines, foods or supplements.

The Company’s intellectual portfoliocurrently consists of two patent families. The first, “Binge BehaviorRegulators,” has been granted in the U.S., Europe, China and India, withpending divisional applications in Europe and the U.S. The second, “AlcoholBeverage Substitute,” has been approved for a European patent, with pendingapplications in the U.S., China and India. The Company intends to seekadditional patents for its compounds whenever warranted and will remainopportunistic regarding the acquisition of additional intellectual property tobuild its portfolio.

Shares of Clearmind are listed fortrading on the Canadian Securities Exchange under the symbol “CMND“and the Frankfurt Stock Exchange under the symbol “CWYO”.

For further information, pleasecontact:

Investor Relations Email:

invest@clearmindmedicine.com

Telephone: (778) 400-5347

General Inquiries Email:

Info@Clearmindmedicine.com

www.Clearmindmedicine.com

FORWARD-LOOKINGSTATEMENTS:

Thisnews release may contain forward-looking statements and information based oncurrent expectations. These statements should not be read as guarantees offuture performance or results. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within therequired timeframe to the satisfaction of the relevant regulators and raisingsufficient financing to complete the Company’s business strategy. There is nocertainty that any of these events will occur. Although such statements arebased on management’s reasonable assumptions, there can be no assurance thatsuch assumptions will prove to be correct. We assume no responsibility toupdate or revise them to reflect new events or circumstances.

Investinginto early-stage companies inherently carries a high degree of risk, andinvestment into securities of the Company shall be considered highlyspeculative.

Thispress release shall not constitute an offer to sell or the solicitation of anoffer to buy, nor shall there be any sale of, the securities in any province inwhich such offer, solicitation or sale would be unlawful. The securitiesissued, or to be issued, under the Private Placement have not been, and willnot be, registered under the United States Securities Act of 1933, as amended,and may not be offered or sold in the United States absent registration or anapplicable exemption from registration requirements.

Neitherthe Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) acceptsresponsibility for the adequacy or accuracy of this release.

WireService Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com

Lamar Odom To Speak At Meet Delic In Las Vegas

Lamar Odom To Speak At Meet Delic In Las Vegas

NBA superstar to speak at Meet Delic in Las Vegas about his embrace of psychedelic treatments and screen the film which chronicles his near-fatal overdose and recovery with psychedelics. He joins world’s leading experts, scientists, and health & wellness advocates to gather for a two-day immersive edutainment experience at AREA15 from November 6 – 7, 2021.

Vancouver, BC, September 28, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on November 7. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers, earning him NBA championships in 2009 and 2010. He joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the goldwinning U.S. men’s basketball team at the 2004 Athens Olympics.

In 2015 Odom was hospitalized in Las Vegas after a near-death overdose that resulted in multiple seizures, strokes and a coma. The upcoming documentary Lamar Odom Reborn chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwork. Odom’s keynote “Fireside Chat: Lamar Odom & Zappy Zapolin: Reborn” will reunite him with the documentary’s director for an intimate discussion of his healing journey with psychedelic medicine and a preview of the film.

“We’re so honored Lamar will be sharing his personal story of healing with all of us at Meet Delic,” said Jackee Stang, co-founder of Delic. “He has shown tremendous courage facing his past traumas and addiction, and his openness to exploring psychedelic treatments is inspiring. We hope his story will open the hearts and minds of more people so we can truly address the growing mental health crisis we’re facing.”

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo. The full lineup of keynote speakers and panelists can be found here.

The twenty hours of panels and keynotes will include an array of topics such as “Why Are Psychedelics Medicine?”, “How Big Money is (Already) Playing Psychedelics,” “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “Microdosing,” “Psychedelic Activism,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.                                                                                                       

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement. 

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com  

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, mjaramillo@labeltheagency.com

MINDCURE to Present at the Benzinga Healthcare Small Cap Conference

MINDCURE to Present at the Benzinga Healthcare Small Cap Conference

VANCOUVER,BC, September28, 2021 /CNW/ – MindCure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH)(“MINDCURE” or the “Company”), a leader inadvanced proprietary technology and research in psychedelics, today announcedthat Kelsey Ramsden, President & CEO of MINDCURE, will present at the BenzingaHealthcare Small Cap Conference, which is being held virtually on September29-30, 2021. Investors can register for the conference here.

In addition, Ms. Ramsden will participate inone-on-one investor meetings during the conference. To schedule a one-on-onemeeting, please contact KCSA Strategic Communications at MindCure@kcsa.com.  

Benzinga Healthcare Small Cap Conference Presentation

Date: Wednesday,September 29, 2021

Time: 4:00 pm ET

Speaker: Kelsey Ramsden, President & CEO of MINDCURE

Link: Healthcare:September 29-30 – Benzinga Small Cap Conference

In other news, the Company also announces ithas granted a total of 10,000 stock options to certain employees pursuant tothe terms the Company’s long term incentive plan (“Plan”). The stock optionsare exercisable at a price of $0.34 per share, and are subject to the terms ofthe Plan. The Company further announces it has issued 59,296 common shares to aconsultant at an agreed-upon price of $0.38 per share.

About Mind Cure Health Inc.

MINDCURE is a life sciencescompany focused on innovating and commercializing new ways to promote healingand improve mental health. The Company is developing digital therapeuticstechnology and researching psychedelic compounds to support access to safe, evidence-basedpsychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board ofDirectors
KelseyRamsden, President & CEO
Phone:1-888-593-8995

Forward-Looking Information

Certaininformation presented in this news release may constitute “forward-lookinginformation” within the meaning of applicable securities laws regardingMINDCURE and its business. Forward-looking information generally can beidentified by the use of terms and phrases such as “anticipate”,”believe”, “could”, “estimate”,”expect”, “feel”, “intend”, “may”,”plan”, “predict”, “project”, “subjectto”, “will”, “would”, and similar terms and phrases.

Forward-lookinginformation is based on a number of key expectations and assumptions made bymanagement of MINDCURE, including, without limitation: the COVID-19 pandemicimpact on the Canadian economy and MINDCURE’s business, and the extent andduration of such impact; no change to laws or regulations that negativelyaffect MINDCURE’s business; there will be a demand for MINDCURE’s products inthe future; no unanticipated expenses or costs arise; MINDCURE will be able tocontinue to identify products that make them ideal candidates for providingsolutions for treating mental health; and that MINDCURE will advance wellnessworldwide.

Forward-lookinginformation is provided for the purpose of presenting information aboutmanagement’s current expectations and plans relating to the future and readersare cautioned that such statements may not be appropriate for other purposes.Forward-looking information inherently entails known and unknown risks anduncertainties about the future and actual results, and involves significantrisks and uncertainties and should not be read as a guarantee of futureperformance or results as actual results may differ materially from thoseexpressed or implied in such forward-looking information. Although MINDCURE hasattempted to identify important factors that could cause actual results,performance or achievements to differ materially from those described in forward-lookinginformation presented, there may be other factors that cause results,performance or achievements to differ from those anticipated, estimated orintended. Accordingly, readers should not place undue reliance on anyforward-looking statements as no forward-looking information can be guaranteed.

Except asrequired by applicable securities laws, forward-looking statements speak onlyas of the date on which they are made and MINDCURE does not undertake anyobligation to publicly update or revise any forward-looking information,whether as a result of new information, future events, or otherwise.

SOURCE Mind Cure Health Inc.

For further information:  

MINDCURE Investor Relations

investors@mindcure.com

1-888-593-8995

Media Inquiries

Annie Graf / Kristin Cwalinski

KCSA Strategic Communications

mindcure@kcsa.com

Lobe Sciences to Present at the Benzinga Healthcare Small Cap Conference

Lobe Sciences to Present at the Benzinga Healthcare Small Cap Conference

Vancouver, British Columbia–(Newsfile Corp. – September 27, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present virtually at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2021.

Philip Young, CEO and Director will begin his presentation at 10:30 A.M. ET on Wednesday, September 29, 2021.

The event is accessible using the following link: https://www.benzinga.com/events/small-cap/healthcare/september-29-track-1/.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Thought Leaders, Entrepreneurs, Medical Experts and Entertainment Headliners include Duncan Trussell, Shane Mauss, Alyson Charles, Dr. Carl Hart, Ifetayo Harvey, Aubrey Marcus…and a surprise special guest speaker

Vancouver, BC, September 23, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today released the full lineup of thought leaders, entrepreneurs, medical experts and entertainers taking part in the two-day premier psychedelics event. The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

The list of thought leaders who will keynote the two-day event taking place from November 6th7th, 2021, at AREA15, an immersive and experiential venue in Las Vegas, includes:

  • Duncan Trussell, stand-up comedian, podcaster and actor, host of The Duncan Trussell Family Hour
  • Jason Silva, Venezuelan-American filmmaker, philosopher, television personality, and public speaker
  • Aubrey Marcus, founder of Onnit, podcast host and best-selling author
  • Alyson Charles, former TV/radio host and athlete turned author, spiritual teacher, medium and shaman
  • Dr. Carl Hart, Ziff Professor at Columbia University, former chair of the Department of Psychology and best-selling author
  • Chris Ryan, PhD, NYT bestselling author and featured speaker at influential conferences such as TED, SXSW, and a frequent guest on The Joe Rogan Experience
  • Ifetayo Harvey, Founder and board president of the People of Color Psychedelic Collective; activist, writer and social media manager at Caring Across Generations
  • George Goldsmith, CEO and founder of COMPASS Pathways and an entrepreneur
  • Ekaterina Malievskaia, MD, Co-founder and Chief Innovation Officer for COMPASS
  • Luke Storey, Motivational speaker, podcaster, writer, meditation and metaphysics teacher, and lifestyle design expert
  • Dr. Molly Maloof, Founder of Adamo Bioscience and a lecturer within the Wellness Department of the Medical School at Stanford University
  • Ben Westhoff, Award-winning investigative reporter who writes about culture, drugs, and poverty
  • Brittany Hoogenboom, Owner and founder of Synergy Soul, a mind, body, soul, & business brand, and an intuitive business coach
  • Dr. Dave Rabin, MD, PhD, Neuroscientist, board-certified psychiatrist, health tech entrepreneur and inventor. Co-founder & Chief Innovation Officer at Apollo Neuroscience
  • Laura Dawn, Msc., Host of The Psychedelic Leadership Podcast, and a microdosing mentor for executives, who has led transformational retreats for over 10 years
  • Shane Mauss, Stand-up comedian, adventurer, podcaster, psychonaut and science enthusiast
  • Kyle Bergquist, Founder of Healing Our Heroes, co-founder of Serving Impact, author and documentary filmmaker
  • Jesse Gould, Psychedelic ranger and founder of Heroic Hearts Project
  • Zappy Zapolin, Futurist, award-winning filmmaker, and psychedelic concierge to the stars
  • Clara Burtenshaw, Partner and investor at Neo Kuma Ventures, the first psychedelics focused venture capital fund in Europe

The following business leaders, scientists and health & wellness advocates will come together for a series of thought-provoking panels on making psychedelics accessible to the masses:

Business Panelists

  • Martin Tobias, Founder of Incisive Ventures, investor and entrepreneur
  • Matt Stang, Pioneer for the cannabis industry in the U.S. and CEO of Delic Corp
  • Mark Goldfogel, Serial entrepreneur and co-founder of KERN, the first cannabis compliance company on NASDAQ
  • Sara Kennedy, Marketing entrepreneur focusing in plant-based particles
  • Joshua White, Co-founder and Executive Director of Fireside Project
  • Mitchell Gomez, Executive Director at DanceSafe
  • Sam Chapman, Executive Director at Healing Advocacy Fund
  • Dr. Markus Roggen, President and Chief Scientific Officer of Delic Labs
  • Donald Gauvreau, Founder, CEO and Chairman at Conscious Mind Labs
  • Ronan Levy, Entrepreneur, founder and Executive Chairman of Field Trip Health
  • Barbara Branaman, Co-Founder and CEO of BioReset Group, Co-Host of the Clarity Cafe Podcast, doctor of Medical Qigong, yoga and meditation teacher
  • Paul Rosen, Founder, CEO and Chairman of Tidal Royalty Corporation
  • Gary Smith, Co-founder and President of Arizona Cannabis Bar Association; author and psychedelic lawyer
  • Kraig Fox, Advisor and entertainment industry superpower ● Nanea Reeves, CEO and co-founder at TRIPP, Inc.
  • Sashko Despotovski, Investor and board member at Delic Corp
  • Dina Burkitbayeva, Founder of PsyMed Ventures, psychedelics biotech investor and entrepreneur
  • Matt Zemon, Chief Strategy Officer and co-founder at Psychable ● Jennifer Pereira, CEO of Bloom Fund and angel investor
  • Kathryn Fantauzzi, CEO and co-founder of Apollo Neuroscience
  • Hanifa Nayo Washington, Sacred activist, co-founder and cultivator of Beloved Community of Fireside Project
  • Lauren Mendelsohn, Esq., Senior associate attorney, Law Offices of Omar Figueroa
  • Sonia Weiss Pick, Co-founder and Managing Director at WPSS Investments
  • Lisa Dannen, MA, Director of Marketing & Communications, Maya Health
  • Dr. Jeff Chen, MD/MBA, Impact entrepreneur, scientist, and storyteller operating at the convergence of culture, science, and business to heal the body, mind, and planet. Cofounder & CEO of Radical Science
  • Ifetayo Harvey will also be taking part in a business panel

Wellness Panelists

  • Adam Bramlage, Founder and CEO ofFlow State, where he works one-on-one with clients to optimize their microdosing experience
  • Phoebe McPherson, Co-founder of the Hearthstone Collective, a mushroom company on a mission to help others heal with plant medicines
  • Jemie Sae Koo, CEO of Psychable.com, an online community dedicated to connecting those interested in legally exploring psychedelic-assisted therapy with practitioners who can support them
  • Victor Mifsud, Creator of the personal feature-length documentary “My Neuroplastic Adventure,” taking viewers from the cutting edge of neuroscience to ancient tribal healing medicines
  • Dr. Stephanie Coleman, MD/MPH, Holistic and psychedelic medicine physician, educator, and entrepreneur
  • Dr. Devon Christie, MD, Clinical instructor with the UBC Department of Medicine and has a focused practice in chronic pain management
  • Will Siu, MD, DPhil, Advisor to Bexson Biomedical and People Science has been trained by MAPS to provide MDMA-assisted therapy
  • Craig Salerno, LAC/LPC, Licensed addiction counselor and licensed professional counselor
  • Sashi Gerzon-Rose, LPC, Psychotherapist, yoga and meditation teacher, and ordained monk in the White Plum lineage of Zen Buddhism
  • David Feifel, MD/PhD, Professor Emeritus of Psychiatry at University of California San Diego and a pioneer in treating mental illness
  • Spencer Hawkswell, CEO at TheraPsilLobbyist, believes responsible drug policy requires effective organization and leadership
  • Deanne Adamson, Founder and President of Being True To You and an addiction specialist
  • Sam Ko, MD/MBA, Founder and Medical Director of Reset Ketamine
  • Lauren Taus, LCSW, Psychotherapist with a specialty in psychedelic assisted therapies
  • Amber Amendola, Psychotherapist with 10 years of health and wellness experience, focused on the healing potential of non-ordinary states of consciousness
  • Robbie Bent, Thought leader in the mental health space building a global community to improve mental health in an accessible way
  • Dr. Matt Cook, President and founder of BioReset™ Medical and Medical Advisor of Bioreset Network.
  • Dr. Harry McIlroy, MD, Family physician, licensed acupuncturist, functional medicine practitioner, osteopath, nutritionist, certified Ashtanga yoga teacher
  • Florencia Bollini, Named “The Corporate Shaman” by Forbes Magazine, one of the pioneering practitioners of the plant medicine world
  • Dr. Dave Rabin, MD, PhD, Laura Dawn, Msc., Jennifer Pereira and Dr. Jeff Chen, MD/MBA, will also be joining the wellness panels

Entertainment

Attendees will be treated to an exciting mix of live music, visual art and dancers on both evenings.

  • The greatest hits of psychedelia past, present and future will be played during The Psyche-Delic Experience, an after-party performance on Saturday, November 6, featuring DJ David Starfire and VJ Jonathan Singer, including a tribute to the Legends of psychedelia featuring the music of The Beatles, Jefferson Airplane, Jimi Hendrix, The Grateful Dead with “appearances” by Alan Watts, Timothy Leary, Terrence McKenna and Ram Das
  • A special tribute performance of Pink Floyd’s “Set The Controls For The Heart Of The Sun” created as a 360 VR immersive film
  • Futuristic psychedelia dance and techno themes featuring the music of Tipper, Sphongle, Desert Dwellers, Bedouin, and all original music by David Starfire with dancers and performance artists
  • MINDCHATTER, a project by singer, songwriter, and producer Bryce Connolly, will provide live music on Sunday, November 6. His complex sound displays influences from electronic, indie, singer-songwriter and hip-hop
  • Dance performances by Little Miss Nasty and visual art by Scott Hedstrom

The twenty hours of panels and keynotes will include an array of topics such as “Psychedelics and the Search for Truth”, “Why Are Psychedelics Medicine?”, “The Shortcomings of Wellness”, “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Psychedelics and Sobriety: The Next Frontier in Recovery“, “Microdosing,” “Psychedelic Activism,” “Digital Dosing: Technology & Innovation Powering Psychedelics”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

           ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement. 

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com  

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Novamind to Present at Benzinga Healthcare Conference

Novamind to Present at Benzinga Healthcare Conference

Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare

TORONTO, ON / September 23, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, will participate in the Benzinga Healthcare Small Cap Conference taking place virtually on September 29-30, 2021.

Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.

Following the panel, from 1:15 PM to 1:30 PM EST, Mr. Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. A short Q&A session will follow.

For more information about the event and to register for free, visit: www.benzinga.com/events/small-cap/healthcare/

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email:media@novamind.ca

Bill Mitoulas, Investor Relations
Email:bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.